Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272 | 1.00 | TSHR (1.00) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL17549552 | 1.00 | TSHR (1.00) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL19410554 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL19410576 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL262589 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23668239 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL15215 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL20543294 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL21834095 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL2786172 | 0.97 | TSHR (0.95) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194452-B1 | ENANTIOPURE OR ENANTIOENRICHED BDDE AND ITS USE AS CROSSLINKING AGENT IN THE MANUFACTURE OF CROSS-LINKED PRODUCTS | GALDERMA SA (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-20120294809-A1 | LANTHANOID COMPLEX CAPSULE AND PARTICLE CONTRAST AGENTS, METHODS OF MAKING AND USING THEREOF | NEW YORK UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294809-A1 | LANTHANOID COMPLEX CAPSULE AND PARTICLE CONTRAST AGENTS, METHODS OF MAKING AND USING THEREOF | LIPA, LPXN, LIPC | TSHR 579/4885ALDH1A1 4658/4885TDP1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.